Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.
BrainsWay Ltd (BWAY) delivers innovative neurostimulation solutions through its FDA-cleared Deep TMS technology, offering noninvasive treatment for mental health disorders. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and corporate developments.
Access timely information about earnings reports, research collaborations, and therapeutic applications of Deep TMS technology. Our curated collection features official press releases and verified news covering treatment efficacy studies, global expansion efforts, and strategic partnerships.
Discover updates on BrainsWay's progress in addressing major depressive disorder, OCD, and addiction treatment through its patented magnetic stimulation platform. The resource serves investors monitoring neurotechnology trends and clinicians seeking evidence-based therapeutic innovations.
Bookmark this page for structured access to BWAY's latest developments in neuromodulation science and mental health treatment advancements. Stay informed about breakthrough clinical data and operational updates from this leader in noninvasive brain stimulation solutions.
BrainsWay Ltd. (NASDAQ: BWAY) will release its third quarter financial results and operational highlights on November 16, 2022, before U.S. market opening. A conference call scheduled for 8:30 AM ET will provide insights into the company’s performance and updates on business operations. BrainsWay specializes in noninvasive neurostimulation treatments for mental health disorders, with FDA-cleared technologies to treat major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The call will be accessible via dial-in and webcast.
BrainsWay Ltd. has appointed Colleen A. Hanlon, Ph.D., a seasoned expert in brain stimulation research, as Vice President of Medical Affairs. Dr. Hanlon, with nearly 20 years of experience, will enhance the integration of medical intelligence for TMS providers and advance patient safety protocols. Previously a professor at Wake Forest University, she has secured over $12 million in NIH funding and published extensively in her field. BrainsWay is a leader in noninvasive neurostimulation treatments, focusing on major depressive disorder, OCD, and addiction.
BrainsWay Ltd. (NASDAQ: BWAY) has launched the Don’t Miss Another Moment sweepstakes to promote the awareness of Deep TMS™ for mental health treatment during Depression Awareness Month. Participants can enter from Oct. 14 to win a $2,000 Airbnb gift card. The campaign targets individuals dealing with mental health disorders, encouraging them to seek help. BrainsWay emphasizes its commitment to advancing neuroscience and supporting those affected by mental illness.
BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 – BrainsWay (NASDAQ: BWAY), a leader in noninvasive neurostimulation treatments, announced a collaboration with NOCD, which specializes in online therapy for obsessive-compulsive disorder (OCD). This partnership aims to enhance awareness and access to effective OCD treatment options. BrainsWay's Deep TMS, FDA-cleared for OCD, will be emphasized alongside NOCD's extensive telehealth platform, ensuring that patients can find suitable treatments more easily. Recently, Cigna expanded coverage for Deep TMS, increasing access for over 86 million adults.
BrainsWay Ltd. (NASDAQ: BWAY) announced President and CEO Christopher von Jako has been named honorary cochair of NAMIWalks Silicon Valley, an event aimed at raising mental health awareness, occurring on October 1, 2022. Dr. von Jako emphasized the importance of community engagement in mental health issues. NAMI Santa Clara County highlighted the walk as a major fundraiser after two challenging years for mental health. BrainsWay, a leader in noninvasive treatments for brain disorders, is committed to increasing access to mental health care through its innovative Deep TMS technology.
BrainsWay Ltd. (NASDAQ: BWAY) announced that Cigna has issued a favorable policy for Deep Transcranial Magnetic Stimulation (TMS) to treat medication-resistant obsessive-compulsive disorder (OCD), effective September 15, 2022. This policy provides access to Deep TMS for patients aged 18 and older after failing multiple medication trials. With Cigna's endorsement, over 86 million adults can now access this innovative treatment. BrainsWay aims to improve healthcare for OCD patients, highlighting that nearly 50% of those with OCD are treatment-resistant.
BrainsWay, a leader in advanced non-invasive treatments for brain disorders, announced that CEO Christopher von Jako will participate in a virtual fireside chat at the H.C. Wainwright Annual Global Investment Conference on September 12, 2022. The event will take place at the Lotte Palace Hotel in New York City. The fireside chat is scheduled for 7:00 a.m. ET. BrainsWay is known for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, which is FDA cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
BrainsWay Ltd. has received FDA 510(k) clearance for its Deep TMS™ H7 Coil, marking the company’s 9th FDA approval. This new clearance allows treatment of adults with major depressive disorder and anxious depression, enhancing options for treatment-resistant patients. A multicenter trial with 144 subjects demonstrated the H7 Coil’s efficacy similar to the existing H1 Coil. This advancement solidifies BrainsWay's commitment to personalized medicine and expands its non-pharmaceutical treatment arsenal.
BrainsWay Ltd. (NASDAQ: BWAY) reported a 14% revenue increase in Q2 2022, totaling $8.0 million, marking its eighth consecutive quarter of growth. The installed base for Deep TMS™ systems rose 22% year-over-year to 829 units. Reimbursement progress included a positive coverage policy from Highmark BCBS for OCD treatment, enhancing eligibility to nearly 70 million lives. However, gross margin decreased to 73% from 81% due to inventory costs and increased international sales. Operating loss widened to $2.0 million compared to $1.5 million in the prior year.
Burlington, Mass. and Jerusalem, July 27, 2022 - BrainsWay Ltd. (BWAY) will report its second quarter financial results before U.S. markets open on August 10, 2022. A conference call will follow at 8:30 AM ET to discuss these results and update on business operations. BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. For further details and to access the call, visit their official website.
